Ep 17. TB Silent Killer

In the 17th episode of Frontline's 31st season titled "TB Silent Killer," the investigative series delves into the global health crisis caused by tuberculosis. Despite being a disease with a cure, TB continues to kill over 1.5 million people annually, with the majority of deaths occurring in low- and middle-income countries.

The episode explores the various factors that contribute to the prevalence of TB, including poverty, lack of access to healthcare, and the rise of drug-resistant strains of the disease. Frontline follows the stories of individuals affected by TB, including patients, healthcare workers, and activists fighting for better treatment and prevention.

The episode also investigates the role of pharmaceutical companies in the fight against TB. With an estimated $10 billion needed annually to combat the disease, there is a growing concern about the high cost of TB drugs and the limited availability of generic alternatives. Frontline examines the complex web of financial incentives, drug patents, and regulatory obstacles that prevent affordable and accessible TB treatment from reaching those who need it most.

Throughout the episode, Frontline highlights the urgent need for a global effort to address the TB epidemic and calls for increased investment in research, development, and access to TB drugs. The program poses important questions about the responsibility of governments, pharmaceutical companies, and global health organizations to prioritize this neglected disease and take action to save lives.

Overall, "TB Silent Killer" is a powerful and thought-provoking episode that shines a light on the devastating toll of TB and the need for a coordinated, collaborative response from the global community. Frontline's in-depth reporting provides valuable insights into the challenges and opportunities in the fight against TB, and offers hope for a future where this deadly disease is no longer a silent killer.